Mutant yeast on drugs

Abstract

Analyzing drug-treated and mutant yeast cells with the new tools of genomics enables the identification of drug targets and should improve the odds of developing useful therapeutics ( pages 1293–1301 ).

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Marton, M.J. et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Med. 4 , 1293–1301 (1998).

  2. 2

    DeRisi, J.L., Iyer, V.R. & Brown, P.O. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278, 680– 686 (1997).

  3. 3

    Wodicka, L., Dong, H., Mittmann, M., Ho, M.-H. & Lockhart, D.J. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nature Biotechnol. 15, 1359 –1367 (1997).

  4. 4

    Cho, R.J. et al. A genome-wide transcriptional analysis of the mitotic cell cycle. Mol. Cell 2, 65–73 (1998).

  5. 5

    Shoemaker, D.D., Lashkari, D.A., Morris, D., Mittmann, M. & Davis, R.W. Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel bar-coding strategy. Nature Genet. 14, 450–456 (1996).

  6. 6

    Gray, N.S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533–538 (1998).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading